Let IPstreet.com help you keep your patent portfolio organized. Organize your patents into groups, related to your product offerings. Identify each patent into a few tiers, where top-tiered patents are of higher commercial importance. This internal ranking can help identify which patents to maintain both domestically and internationally. Additionally, such a simple ranking will allow for establishing strategic enforcement guidelines. Resources are limited, so knowledge to identify which patents are most important can result in better utilization of resources. Using our patent search tools, you can better understand the value of a patent and analytics behind it.

Conducting a thorough patent search is difficult, particularly for the novice. Patent searching is a learned skill. A novice in the United States could contact the nearest Patent and Trademark Depository Library (PTDL) and seek out search experts to help in setting up a search strategy.

In order to be SOX compliant, it is imperative that you keep track of your patent portfolio. A thorough IP audit requires organization. Ironically, companies will pay more for the procurement of patents than they will for organizing and managing IP portfolios. With IP Street, we can help you navigate your own IP landscape and quickly organize your portfolios. With our promise of ongoing innovation, we can further develop tools you need to make this organization possible.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

Hello and welcome to our little slice of the World, a place where passion and opinions run high in our niche area, which just so happens to be the world of patents, innovation, technology, business and other areas of intellectual property. Although Lewis Lee, our founder, is a patent attorney, and many of the contributors to our content are IP counselors, the content should NOT be considered to be legal advice, but rather are intended to be informational. No attorney-client relationship is established through your use of IP Street. For more information please check our Disclaimer, Terms & Conditions and our Privacy Policy.